Immuneering Corporation (IMRX) 銘柄情報

IMRX........................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

IMRX news
https://ih.advfn.com/markets/nasdaq/afterhours

IMRX under $2

IMRX.....................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

IMRX under $2

Peter Feinberg, recently bought US$183k worth of stock, paying US$2.44 for each share

A lot to like except the share price sadly.

Results:IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models.
IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.
In a human pancreatic cancer cell line (MIA PaCa-2) tumor xenograft model, IMM-1-104 alone showed greater tumor growth inhibition (TGI) and better durability than any single or combination chemotherapy tested.
At day 39, antitumor activity (TGI%) was 103% for IMM-1-104 at 125 mg/kg BID PO, 25.2% for GEM at 60 mg/kg IP Q4D, 62.2% for PAC at 10 mg/kg IV Q4D, and 36.6% for 5FU at 50 mg/kg IP Q4D.
In the Phase 2a portion of Immuneering’s ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in select combinations with approved chemotherapeutic agents. The Phase 2a portion includes five arms, three of which focus on patients with pancreatic cancer. Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting. The company expects initial data from multiple Phase 2a arms in 2024.
https://ir.immuneering.com/news-releases/news-release-details/imm-1-104-synergistic-chemotherapy-pancreatic-cancer-models

The top 5 shareholders own 54% of the company

the third-largest shareholder, also happens to hold the title of Member of the Board of Directors

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Company expects multiple readouts from its Phase 1/2a clinical trial in 2024

Peter Feinberg, recently bought US$183k worth of stock, paying US$2.44 for each share.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imrx/immuneering/news/insider-spends-us183k-buying-more-shares-in-immuneering

It’s easy to find in the filings. Not that is has helped the share price any.

how do you know insider buying has occurred for IMRX???

Good to see that insider buying! Give it a week or two and I wouldn‘t be surprised to see it trading back between $5 to $6. Certainly no need to be a seller now. Have a great day all and God bless!

IMRX................................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783

Should be back over $5 soon.

management started dosing patients in the phase IIa portion of the study. This portion will evaluate a 320mg dose of IMM-1-104 as monotherapy in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and melanoma, and as combination therapy in PDAC.

Initial data from the phase IIa portion is expected later this year

IMRX under $2

IMRX new 52. Lo

Maybe insiders got some news, like dilution is coming to pay for Phase 2.

IMRX fell today after positive results...